New and Exciting Lyme Disease Research
By Lyn Hanshew, M.D.
Some of the most ill people I have tried to help have been diagnosed with Lyme disease. Conventionally, the diagnostic and treatment options are not good. Serological testing has been disappointing and confusing.
The difficulties with long-term antibiotic protocols include the expense, immune suppression, lack of insurance coverage, side-effects, potential for development of resistance and lack of studies demonstrating efficacy.
Countless people needlessly suffer from Lyme disease. After years of research I now present what I believe to be the most effective Lyme disease immune support system offered today.
Understanding the Cause of Lyme Disease
Lyme disease was first recognized in 1975 when mothers in Lyme, Connecticut, notified researchers that many of their children had been diagnosed with rheumatoid arthritis. Dr. Burgdorfer in 1981 discovered the spirochete Borellia burgdorferi that was transmitted from the deer tick to humans. In the US alone, over 300,000 new cases of Lyme disease are reported annually. It is the number one, vector-borne illness in the US, and is rapidly advancing worldwide. Lyme disease is difficult to diagnose due to inconsistent lab test results and patient history that may or may not include a known tick bite or bull’s eye lesion, arthritis, muscle weakness, memory loss and mood disorders including depression and anxiety.
ACS 200 Extra Strength: Anti-bacterial, Anti-viral and Anti-fungal
ACS 200 Extra Strength is the only antimicrobial proven to kill Borrelia burgdorferi and coinfection agent Powassan virus. The leading silver-based supplement, ACS 200 achieved 99.9999% (complete) kill against Borrelia burgdorferi in less than 8 minutes as determined by independently-derived, in vitro, benchmark kill-time studies. This data provides the scientific basis for using ACS 200 as an effective anti-Borrelia agent. In the clinical setting, many practitioners currently prescribe ACS 200 to their Lyme patients with excellent outcomes.
Dr. Burgdorfer described similar in vitro testing results using a silver preparation. He surmised that silver disables the enzyme(s) used by bacterial, fungal and viral agents for their oxygen metabolism causing them to suffocate upon contact. There have been reports of elimination of late-stage Lyme symptoms using ACS 200 Extra Strength.
ACZ nano Extra Strength: Remove Toxic Heavy Metals, Reduce Herxheimer
Most sufferers of Lyme disease suffer from toxicity of heavy metals. Heavy metal toxicity suppresses immune function and prevents healing.
A powerful oral detoxification agent, ACZ nano selectively and irreversibly binds and excretes toxic heavy metals, such as Mercury and Lead, chemical toxins, radioactive toxins and free radicals via the urinary tract, without removing vital nutrients. These results have been verified in multiple, independent urine challenge studies. Removing damaging toxins is vital for Lyme sufferers if health is to be restored.
As ACS 200 kills the Lyme-associated B. burgdorferi, various toxins are released and can cause a “die-off” or “herxheimer reaction”. ACZ nano Extra Strength mitigates typical die-off reaction by binding toxins and sub-particles released from the dying Lyme organisms. ACZ nano also increases alkalinity by binding free radicals and acids. Tissue alkalinity is required for the body to heal, especially the neurological system in people affected by Lyme disease.
ACG Glutathione Extra Strength: Glutathione (GSH) is the most important intracellular anti-oxidant of the entire body: protecting, healing and rejuvenating
GSH is especially important for brain cells and other components of the nervous system at risk for damage from the highly toxic Lyme organism, B. burgdorferi. The tri-peptide, Glutathione is the most important anti-oxidant in the body. GSH prevents damage to important cellular components caused by reactive oxygen species, such as free radicals and peroxides.
Low Glutathione levels are proven to make us susceptible to chronic illness. The latest research shows that nearly all chronically ill patients suffer from Glutathione deficiency.
ACG Glutathione Extra Strength intra-oral spray is an important breakthrough in GSH supplementation. Previously, the only effective route of administration was IV and very expensive. Independent clinical research has demonstrated an increase of intracellular levels of GSH by over 10% after only 7 hours of intra oral administration of ACG Glutathione.
Neuro Care Extra Strength: Neurological System Rejuvenation
Lyme disease can cause significant neurological issues, resulting in migraine headaches and severe brain fog to name a few. Neuro Care Extra Strength improves memory, alertness, improves mood, cognitive performance, psychomotor functions and mental clarity and increases cerebral blood flow; reduces mental anxiety and stress; specifically on brain cells.
Neuro Care Extra Strength also reduces neuroinflammation, acts as a neuroprotector and affects the central nervous system.
There are complex factors that contribute to the many health issues associated with Lyme disease. When taken together, the Ultimate Lyme Support System is highly effective in broad support.
About the Author
Dr. Hanshew practiced medicine on the seaside of Seattle for 15 years. She achieved Board-Certified in Family Medicine and Bariatric Medicine. She also has specialized training in Anti-Aging Medicine, Natural Hormone Replacement and Environmental Toxicity issues relating to the exponential rise in the incidence and successful treatment of Autism, Fibromyalgia, ADD, Chronic Fatigue, Multiple Sclerosis, Obesity, Anxiety, Depression and Cancer.
1. Burgdorfer, William. “From Penicillin to Mild Silver Protein-An Answer to Lyme Disease Without Antibiotics”. Rocky Mountain Labortories, Division of N.I.H.
2. Cairns V, Godwin J (2005). “Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms”. Int J Epidemiol 34 (6): 1340–1345.
3. Singh SK, Girschick HJ (July 2004). “Lyme borreliosis: from infection to autoimmunity”. Clin. Microbiol. Infect. 10 (7): 598–614.
4. Stricker RB (July 2007). “Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease”. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 (2): 149–57.
5. Klempner MS, Hu LT, Evans J, et al. (July 2001). “Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease”. N. Engl. J. Med. 345 (2): 85–92.
6. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA (March 2008). “A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy”. Neurology 70 (13): 992–1003.
7. Krupp LB, Hyman LG, Grimson R, et al. (24 June 2003). “Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial”. Neurology 60 (12): 1923–30.
8. Feder HM, Johnson BJ, O’Connell S, et al. (October 2007). “A critical appraisal of “chronic Lyme disease””. N. Engl. J. Med. 357 (14): 1422–30.
9. Steere AC, Sikand VK, Schoen RT, Nowakowski J (2003). “Asymptomatic infection with Borrelia burgdorferi”. Clin. Infect. Dis. 37 (4): 528–532.
10. Fahrer H, Sauvain MJ, Zhioua E, Van Hoecke C, Gern LE (1998). “Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?”. Eur. J. Epidemiol. 14 (2): 117–123.
11. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC (March 2002). “Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans”. Ann. Intern. Med. 136 (6): 421–428.
12. Auwaerter PG, Aucott J, Dumler JS (January 2004). “Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment”. Expert Rev Mol Med 6 (2): 1–22.
13. Steere AC, Dhar A, Hernandez J, et al. (January 2003). “Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease”. Am. J. Med. 114 (1): 58–62.
14. Dandache P, Nadelman RB (June 2008). “Erythema migrans”. Infect. Dis. Clin. North Am. 22 (2): 235–60.Stanek G, Strle F (June 2008). “Lyme disease: European perspective”. Infect. Dis. Clin. North Am. 22 (2): 327–39.
15. Chabria SB, Lawrason J (2007). “Altered mental status, an unusual manifestation of early Disseminated Lyme disease: A case report”. Journal of Medical Case Reports 1 (1): 62.
16. Shadick NA, Phillips CB, Sangha O, et al. (December 1999). “Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease”. Ann. Intern. Med. 131 (12): 919–26.
17. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (February 2000). “Long-term outcomes of persons with Lyme disease”. JAMA 283 (5): 609–16.
18. Hess A, Buchmann J, Zettl UK, et al. (1999). “Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenia-like disorder”. Biol. Psychiatry 45 (6): 795.
19. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289– 300, vi–vii.
20. Mullegger RR (2004). “Dermatological manifestations of Lyme borreliosis”. Eur J Dermatol 14 (5): 296–309.
21. Tilly K, Rosa PA, Stewart PE (June 2008). “Biology of infection with Borrelia burgdorferi”. Infect. Dis. Clin. North Am. 22 (2): 217–34,
22. Lo Re V, Occi JL, MacGregor RR (April 2004). “Identifying the vector of Lyme disease”. Am Fam Physician 69 (8): 1935–7.
23. Steere AC (July 2001). “Lyme disease”. N. Engl. J. Med. 345 (2): 115–25.
24. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289–300, vi–vi.
25. Tylewska-Wierzbanowska S, Chmielewski T. (Jul 2002) “Limitation of serological testing for Lyme borreliosis evaluation of ELISA and western blot in comparison with PCR and culture methods”. Wien Klin Wochenschr 114(13- 14):601-5.